Investors favor Eli Lilly over Novo Nordisk in obesity drug race

The discrepancy in market sentiment reflects concerns over long-term stability rather than immediate financial performance. Lilly continues to consistently outperform expectations, strengthening its grip on the rapidly expanding obesity drug sector. In contrast, Novo Nordisk struggles to reassure investors regarding its drug pipeline and the sustainability of its growth trajectory.

BMO Capital Markets analyst Evan Seigerman noted that while Novo Nordisk’s decision to raise guidance was anticipated, the path forward remains obscured. The market is currently prioritizing the clear, high-growth momentum demonstrated by Lilly over the corrective measures still being implemented by its competitor.